(Total Views: 536)
Posted On: 07/18/2023 8:45:06 AM
Post# of 154133
Ohm's on the mark analysis.
"Cytodyn has not said data retrieval is impossible. Cytodyn thinks it's not worthwhile.
With Cabenuva on the market using monthly injections leronlimab's market has shrunk. Then we have to look at how long and costly it will be to retrieve all the data and reassemble it into a viable BLA. That is scarce money that Cytodyn thinks is better used for NASH."
HIV medical science has moved on without us. Nash it is.
Read More: https://investorshangout.com/post/view?id=659...z87oo2JOAr
"Cytodyn has not said data retrieval is impossible. Cytodyn thinks it's not worthwhile.
With Cabenuva on the market using monthly injections leronlimab's market has shrunk. Then we have to look at how long and costly it will be to retrieve all the data and reassemble it into a viable BLA. That is scarce money that Cytodyn thinks is better used for NASH."
HIV medical science has moved on without us. Nash it is.
Read More: https://investorshangout.com/post/view?id=659...z87oo2JOAr
(3)
(0)
